Marcain (Bupivacaine Hydrochloride)

Bupivacaine Hydrochloride blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and spread of action potentials. This interruption of nerve impulse conduction results in loss of sensation in the area supplied by the targeted nerves, delivering a prolonged anesthetic effect.

The appropriate dose of Marcain is determined by the prescribing clinician based on the patient’s age, weight, health status, and the specific procedure. No fixed regimen is provided; the prescriber selects the concentration and volume required for safe and effective anesthesia.

Safety of Marcain during pregnancy or lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

To order Marcain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Marcain (bupivacaine) has a longer duration of action than lidocaine, making it preferable for procedures requiring extended analgesia. However, bupivacaine carries a higher risk of cardiotoxicity at elevated plasma levels, so careful dosing and monitoring are essential compared with lidocaine’s shorter‑acting profile.

Marcain should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use, and discard any solution that appears discolored or contains particles.

Marcain is administered by infiltration, peripheral nerve block, or epidural injection. The solution is injected directly into the target tissue or space using aseptic technique, often under ultrasound or nerve stimulator guidance to ensure accurate placement.

Serious risks include cardiac arrhythmias, severe hypotension, seizures, respiratory depression, and anaphylactic reactions. Immediate monitoring of cardiovascular and central nervous system parameters is essential, and any signs of toxicity require prompt medical intervention.

Marcain is contraindicated in patients with known hypersensitivity to bupivacaine, other amide‑type local anesthetics, or any of the product’s excipients. Caution is also advised for individuals with severe hepatic impairment, existing cardiac conduction disorders, or those receiving interacting medications listed under major interactions.